BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Bronchitol mannitol: Completed Phase III enrollment

Pharmaxis completed enrollment of 474 patients in a double-blind, placebo-controlled, international Phase III trial (DPM B305) evaluating twice-daily 400 mg inhaled Bronchitol for 52 weeks.

Bronchitol is approved in Australia to treat cystic fibrosis as an...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >